Table 4 Immunophenotypic features of ALK... | American Society of Hematology

Table 4

Immunophenotypic features of ALK⁺ and ALK⁻ ALCL, and PTCL-NOS

Immunophenotype	ALK⁺, %	ALK⁻, %	P*	PTCL-NOS, %	P†	PTCL-NOS CD30⁺ > 80%, %	P‡
CD30	100	100	—	32	< .001	100	—
CD2	23	59	< .001	86	< .001	73	.38
CD3	12	45	< .001	93	< .001	80	.02
CD4	40	35	.44	56	.002	27	.70
CD8	5	10	.34	19	.21	20	.37
TIA1, granzyme B, or perforin	80	66	.09	32	< .001	27	< .009
EMA	83	43	< .001	3	< .001	0	.008
CD56	7	4	.32	6	.56	0	.80
CD43	44	50	1.0	93	.003	80	.23

Immunophenotype	ALK⁺, %	ALK⁻, %	P*	PTCL-NOS, %	P†	PTCL-NOS CD30⁺ > 80%, %	P‡
CD30	100	100	—	32	< .001	100	—
CD2	23	59	< .001	86	< .001	73	.38
CD3	12	45	< .001	93	< .001	80	.02
CD4	40	35	.44	56	.002	27	.70
CD8	5	10	.34	19	.21	20	.37
TIA1, granzyme B, or perforin	80	66	.09	32	< .001	27	< .009
EMA	83	43	< .001	3	< .001	0	.008
CD56	7	4	.32	6	.56	0	.80
CD43	44	50	1.0	93	.003	80	.23

Information missing: granzyme B, 60% ALK⁻; 75% ALK⁺; and 80% PTCL-NOS; perforin, 72% ALK⁻; 95% ALK⁺; and 98% PTCL-NOS; CD43, 81% ALK⁻; 82% ALK⁺; and 92% PTCL-NOS; EMA, 41% ALK⁻; 45% ALK⁺; and 91% PTCL-NOS.

ALK⁺ versus ALK⁻.

†

ALK⁻ versus PTCL-NOS.

‡

ALK⁻ versus PTCL-NOS more than 80% CD30⁺ cells.

View Large

This Feature Is Available To Subscribers Only